OA09884A - Imidazolyl-Alkenoic Acids - Google Patents

Imidazolyl-Alkenoic Acids

Info

Publication number
OA09884A
OA09884A OA60471A OA60471A OA09884A OA 09884 A OA09884 A OA 09884A OA 60471 A OA60471 A OA 60471A OA 60471 A OA60471 A OA 60471A OA 09884 A OA09884 A OA 09884A
Authority
OA
OAPI
Prior art keywords
imidazolyl
alkenoic acids
alkenoic
acids
Prior art date
Application number
OA60471A
Other languages
English (en)
Inventor
Keenan Richard Mcculloch
Joseph Weinstock
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of OA09884A publication Critical patent/OA09884A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA60471A 1991-08-14 1994-02-10 Imidazolyl-Alkenoic Acids OA09884A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/746,262 US5185351A (en) 1989-06-14 1991-08-14 Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists

Publications (1)

Publication Number Publication Date
OA09884A true OA09884A (en) 1994-09-15

Family

ID=25000103

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60471A OA09884A (en) 1991-08-14 1994-02-10 Imidazolyl-Alkenoic Acids

Country Status (32)

Country Link
US (1) US5185351A (ref)
EP (1) EP0641203B1 (ref)
JP (1) JPH07500579A (ref)
CN (1) CN1036396C (ref)
AP (3) AP527A (ref)
AT (1) ATE226073T1 (ref)
AU (1) AU667824B2 (ref)
BG (1) BG61593B1 (ref)
BR (1) BR9206443A (ref)
CA (1) CA2115170C (ref)
CZ (1) CZ281635B6 (ref)
DE (1) DE69232817T2 (ref)
DK (1) DK0641203T3 (ref)
ES (1) ES2185617T3 (ref)
FI (1) FI114796B (ref)
HU (1) HU225048B1 (ref)
IL (1) IL102813A (ref)
MA (1) MA22626A1 (ref)
MX (1) MX9204737A (ref)
MY (1) MY110205A (ref)
NO (1) NO305172B1 (ref)
NZ (1) NZ243966A (ref)
OA (1) OA09884A (ref)
PL (1) PL177234B1 (ref)
PT (1) PT100779B (ref)
RO (1) RO113643B1 (ref)
RU (1) RU2124513C1 (ref)
SK (1) SK281252B6 (ref)
TW (1) TW234690B (ref)
UA (1) UA40587C2 (ref)
WO (1) WO1993003722A1 (ref)
ZA (1) ZA926133B (ref)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
WO1992010189A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US6028091A (en) * 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5447949A (en) * 1991-05-15 1995-09-05 Smithkline Beecham Corporation N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
US20030166700A1 (en) * 1991-12-12 2003-09-04 Smithkline Beecham P.L.C. Medicament
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
DE4206043A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazole
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5719293A (en) * 1994-05-20 1998-02-17 Smithkline Beecham Corporation Intermediate for preparing a pharmaceutically active compound
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6420412B2 (en) 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
AR006439A1 (es) * 1996-03-29 1999-08-25 Smithkline Beecham Corp Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
AR011125A1 (es) 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
ZA984421B (en) * 1997-05-27 1998-11-27 Smithkline Beecham Corp Method of treating isolated systolic hypertension
EP0991647B1 (en) * 1997-06-27 2002-09-04 Smithkline Beecham Corporation Eprosartan monohydrate
US6630498B2 (en) 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
NZ502644A (en) * 1997-08-06 2002-03-01 Smithkline Beecham Corp Eprosartan arginyl charge-neutralization-complex useful for treating diseases where blockade of the angiotensin II receptor is indicated
PL340587A1 (en) * 1997-11-17 2001-02-12 Smithkline Beecham Corp Oral preparations of high therapeutic substance content with instantaneous or modifiable release of such substance and methods of obtaining them
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
AU763309B2 (en) * 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
JP2002521373A (ja) 1998-07-24 2002-07-16 バイエル アクチェンゲゼルシャフト 置換されたベンゾイルシクロヘキサンジオン類
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19946853A1 (de) 1999-09-30 2001-04-05 Bayer Ag Substituierte Arylketone
DE10004084A1 (de) * 2000-01-31 2001-08-02 Bayer Ag Substituierte Imid-Derivate
DE10221121A1 (de) * 2002-05-13 2003-12-04 Bayer Cropscience Ag N'-Cyano-N-methyl-imidamid-Derivate
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
JP4829115B2 (ja) * 2003-10-10 2011-12-07 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 選択的ｉ１イミダゾリンレセプターアゴニストおよびアンギオテンシンｉｉレセプターブロッカーを含有する医薬組成物
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007066678A1 (ja) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
US20080014263A1 (en) * 2006-07-17 2008-01-17 Glenmark Pharmaceuticals Limited Amorphous eprosartan mesylate and process for the preparation thereof
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
EP2097408A4 (en) * 2006-12-27 2010-08-25 Hetero Drugs Ltd IMPROVED PROCESS FOR THE PREPARATION OF EPROSARTAN
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8361507B2 (en) * 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2295431A3 (en) * 2007-07-25 2011-08-03 Hetero Drugs Limited Substantially pure eprosartan free base
AU2008315651B2 (en) * 2007-10-22 2012-12-13 Orchid Research Laboratories Limited Histone deacetylase inhibitors
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101215284B (zh) * 2007-12-31 2010-10-13 浙江华海药业股份有限公司 一种改进的依普罗沙坦的制备方法
WO2009122421A2 (en) * 2008-03-31 2009-10-08 Hetero Research Foundation Improved process for eprosartan intermediate
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2011004384A2 (en) 2009-06-05 2011-01-13 Glochem Industries Limited Process for the preparation of eprosartan
WO2011051975A1 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
RU2525156C2 (ru) * 2010-07-15 2014-08-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX2014002163A (es) 2011-08-26 2014-09-25 Wockhardt Ltd Métodos para el tratamiento de desórdenes cardiovasculares.
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3025711B1 (en) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108778334A (zh) 2016-03-24 2018-11-09 第三共株式会社 用于治疗肾脏疾病的药物
JP2021528735A (ja) 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
FI3911648T3 (fi) 2019-01-18 2025-01-10 Astrazeneca Ab 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS58157768A (ja) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0403159B1 (en) * 1989-06-14 2000-03-01 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
GB9027197D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027209D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
WO1992010189A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
GB9027212D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027201D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
ATE177634T1 (de) * 1990-12-14 1999-04-15 Smithkline Beecham Corp Angiotensin-ii-rezeptor blockierende zusammensetzungen

Also Published As

Publication number Publication date
AP9500741A0 (en) 1995-07-31
IL102813A (en) 1999-07-14
HU9400413D0 (en) 1994-05-30
AP526A (en) 1996-09-06
CA2115170C (en) 2004-05-25
RU2124513C1 (ru) 1999-01-10
CZ281635B6 (cs) 1996-11-13
SK13594A3 (en) 1994-08-10
FI940642L (fi) 1994-02-11
HU225048B1 (en) 2006-05-29
US5185351A (en) 1993-02-09
CA2115170A1 (en) 1993-03-04
AU667824B2 (en) 1996-04-18
FI940642A0 (fi) 1994-02-11
AP9200416A0 (en) 1992-10-31
MY110205A (en) 1998-02-28
NO940476D0 (no) 1994-02-11
PT100779A (pt) 1993-09-30
HK1012246A1 (en) 1999-07-30
AP525A (en) 1996-09-06
EP0641203A1 (en) 1995-03-08
HUT70157A (en) 1995-09-28
NO940476L (no) 1994-04-11
NO305172B1 (no) 1999-04-12
BG61593B1 (bg) 1998-01-30
JPH07500579A (ja) 1995-01-19
EP0641203A4 (en) 1994-06-09
PT100779B (pt) 1999-07-30
RO113643B1 (ro) 1998-09-30
WO1993003722A1 (en) 1993-03-04
AU2475692A (en) 1993-03-16
DE69232817T2 (de) 2003-06-18
IL102813A0 (en) 1993-01-31
DE69232817D1 (de) 2002-11-21
DK0641203T3 (da) 2003-02-17
EP0641203B1 (en) 2002-10-16
ES2185617T3 (es) 2003-05-01
BR9206443A (pt) 1994-09-27
CN1036396C (zh) 1997-11-12
AP9500742A0 (en) 1995-07-31
AP527A (en) 1996-09-06
CN1070645A (zh) 1993-04-07
FI114796B (fi) 2004-12-31
BG98454A (bg) 1995-02-28
ZA926133B (en) 1993-03-31
CZ31194A3 (en) 1994-12-15
MA22626A1 (fr) 1993-04-01
MX9204737A (es) 1994-02-28
TW234690B (ref) 1994-11-21
PL177234B1 (pl) 1999-10-29
SK281252B6 (sk) 2001-01-18
NZ243966A (en) 1996-08-27
ATE226073T1 (de) 2002-11-15
UA40587C2 (uk) 2001-08-15

Similar Documents

Publication Publication Date Title
IL102813A0 (en) Imidazolyl-alkenoic acids
ZA922420B (en) Grf-analogs ii
GB9325558D0 (en) Percaboxylic acids
EP0563238A4 (en) Imidazolyl-alkenoic acids
ZA919058B (en) Sulfimidoperoxycarboxylic acids
IE900337L (en) Heteroaryl-1-alkyl-pyrrole-2-carboxylic acids
IE900338L (en) Heteroaryl-1-alkyl-pyrrole-2-carboxylic acids
IE900361L (en) Saccharoascorbic acids
ZW9390A1 (en) Imidazolyl-alkenoic acids
ZA933757B (en) Cyclopentane-and-pentene-beta-amino acids
CA68731S (en) Moneybox
DE59207864D1 (en) Koagulationssonde
AU204P (en) NIRIBI Chamelaucium uncinatum
AU205P (en) TARANNA Danthonia richardsonii
AU213P (en) MOONBEAM Galtonia candicans
AU352P (en) TRIUMPHANT Chamelaucium uncinatum
CA69416S (en) Orgnizer
GB9121278D0 (en) Ester
IE901193L (en) 5-alkylquinolone carboxylic acids
DE4290202D2 (de) Streifenvorhang
GB9112796D0 (en) Nucleic acids
GB9126359D0 (en) Nucleic acids
GB9112118D0 (en) Signmate ii
AU113064S (en) Wearstud
AU112054S (en) Airfreshener